Ovation Science, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Terry H. Howlett
- Full Time Employees
- 5
- Sector
- Consumer non-durables
- Industry
- Household/Personal care
- Address
- 1003-1166 Alberni Street Vancouver BC Canada V6E 3Z3
- IPO Date
- Nov 15, 2018
- Website
- ovationscience.com
- Similar Companies
- Business
- Ovation Science Inc. operates as a drug development company specializing in the research, development, and licensing of proprietary topical and transdermal cannabis and hemp-derived cannabinoid products powered by its patented Invisicare® skin delivery technology. The company offers a portfolio of products including topical and transdermal creams and lotions designed for health and wellness, pain relief, and skincare applications, marketed under its Invibe® MD health and wellness line and ARLO CBD Beauty anti-aging skincare line. Ovation Science licenses its Invisicare® polymer technology to partners who manufacture and distribute the branded products primarily in Canada and the United States. Founded in 2016 and headquartered in Vancouver, British Columbia, Ovation Science focuses on out-licensing its patented delivery technology and product formulations to national and international cannabis companies, enabling them to produce and market these products globally without direct involvement in manufacturing or distribution. Recent major developments include an exclusive licensing agreement with MidWest Roots, LLC for topical and transdermal cannabis formulations in Missouri, and a strategic enhancement of its partnership with Skinvisible Pharmaceuticals to leverage patented cannabinoid delivery technology for obesity and metabolic health markets. Additionally, Ovation Science expanded its market reach through product launches with Planet 13 in Nevada and continues to extend its distribution channels and license agreements to scale commercial operations. Ovation's latest strategy emphasizes innovation in cannabinoid delivery, entry into adjacent markets like obesity therapy through collaboration, and growth in branded topical cannabis health products, demonstrating a commitment to expanding its presence in the North American cannabis market while maintaining a technology-centric business model focused on licensed manufacturing and marketing partnerships. Its operations also include a wholly owned U.S. subsidiary, Ovation Science USA Inc., supporting its commercial activities in the American market. The company's technology and product innovation remain central to its competitive positioning in the cannabinoid topical and transdermal sector.
Company News
Ovation Science Secures New Canadian Patent; Strengthening IP Position and Expanding Commercial Opportunities for Topical Cannabis Products
Ovation Science Sees Expanded Opportunities for Its Topical Products Following U.S. Cannabis Rescheduling
Ovation Science and Skinvisible Pharmaceuticals Enhance Their Strategic Partnership in the Obesity Market with Innovative Cannabinoid Delivery Technology with New Developments and Patent Protection
Ovation Science Expands with Planet 13 into Florida
Ovation Science Licensee Launches Innovative Transdermal Cannabis Products in Pennsylvania
Ovation Science Topicals Launch with Planet 13 in Nevada
Planet 13 Launches New MEDIZIN Branded Topicals - Introducing MEDIZIN Rest, Recovery and Relief
Ovation Science Expands Market Reach with Exclusive Canadian License Agreement
Ovation Science Announces License Agreement for Its Topical / Transdermal Cannabis Products for Missouri
Ovation Science Signs License Agreement with Planet 13 for Its Topical / Transdermal Cannabis Products for Nevada